Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
The campaign aims to promote women’s health and wellness and urge them to visit the hospital for key medical check-ups
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Subscribe To Our Newsletter & Stay Updated
